A Study of 2-dose Vaccination Regimen of Ad26.ZEBOV and MVA-BN-Filo in Infants

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

108 participants

Study Classification

INTERVENTIONAL

Study Start Date

2019-08-19

Study Completion Date

2022-09-28

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to assess the safety and reactogenicity of a heterologous 2-dose regimen utilizing Ad26.ZEBOV (first vaccination; Dose 1) and MVA-BN-Filo (second vaccination; Dose 2) administered intramuscularly (IM) on Days 1 and 57, respectively (Main Study) and also to provide the heterologous 2-dose vaccination regimen (Ad26.ZEBOV on Day 1 and MVABN-Filo on Day 57) to participants in the control arm of the main study (Extension Phase).

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Ad26.ZEBOV, MVA-BN-Filo Vaccination in Children and Adults Previously Vaccinated With Control in the EBOVAC-Salone Study

NCT05284097

Virus Diseases Hemorrhagic Fever, Ebola Infections +8 more

COMPLETED PHASE2

A Study of a 2-dose Ebola Vaccine Regimen of Ad26.ZEBOV Followed by MVA-BN-Filo in Healthy Pregnant Women

NCT04556526

Healthy

COMPLETED PHASE3

A Study to Assess Safety, Tolerability, and Immunogenicity of Three Heterologus 2-dose Regimens of the Candidate Prophylactic Vaccines for Ebola in Healthy Adults

NCT02416453

Ebola Viral Disease

COMPLETED PHASE2

Ad26.ZEBOV Booster in Children Previously Vaccinated With Ad26.ZEBOV and MVA-BN-Filo (EBOVAC Booster Study)

NCT04711356

Ebola Virus Disease

COMPLETED PHASE2

Effectiveness and Safety of a Heterologous, Two-dose Ebola Vaccine in the DRC

NCT04152486

Ebola Virus Disease

UNKNOWN PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Ebola Virus Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

PREVENTION

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Arm 1: Ad26.ZEBOV, MVA-BN-Filo

Participants will be administered 0.5 mL of Ad26.ZEBOV vaccine (5\*10\^10 viral particles \[vp\]) on Day 1 by intramuscular (IM) injection followed by 0.5 mL of MVA-BN-Filo (1\*10\^8 infectious units \[Inf U\]) vaccine by IM injection on Day 57. Participants will also receive a dose of MenACWY at the 6-months post-dose-2 visit. Upon completion of the main study, participants in the extension phase who were originally randomized to the control arm will receive the same vaccine regimen as the participants in the Ad26.ZEBOV, MVA-BN-Filo arm of the main study.

Group Type EXPERIMENTAL

Ad26.ZEBOV

Intervention Type BIOLOGICAL

Participants will receive 0.5 mL IM injection of Ad26.ZEBOV as first vaccination.

MVA-BN-Filo

Intervention Type BIOLOGICAL

Participants will receive 0.5 mL IM injection of MVA-BN-Filo as second vaccination.

MenACWY

Intervention Type BIOLOGICAL

Participants will receive 0.5 mL IM injection of MenACWY.

Arm 2: MenACWY

Participants will be administered 0.5 mL of MenACWY vaccine by IM injection on Day 1 and Day 57. Participants will also receive a dose of MenACWY at the 6-months post-dose-2 visit.

Group Type ACTIVE_COMPARATOR

MenACWY

Intervention Type BIOLOGICAL

Participants will receive 0.5 mL IM injection of MenACWY.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Ad26.ZEBOV

Participants will receive 0.5 mL IM injection of Ad26.ZEBOV as first vaccination.

Intervention Type BIOLOGICAL

MVA-BN-Filo

Participants will receive 0.5 mL IM injection of MVA-BN-Filo as second vaccination.

Intervention Type BIOLOGICAL

MenACWY

Participants will receive 0.5 mL IM injection of MenACWY.

Intervention Type BIOLOGICAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Parent(s) (preferably both if available or as per local requirements)/guardian must sign an informed consent form (ICF) indicating that he or she understands the purpose of, and procedures required for the study, and potential risks and benefits of the study, and are willing to allow their child to participate in the study
* Parent(s)/guardian are willing/able to ensure that their child adheres to the prohibitions and restrictions
* The parent(s)/guardian must be at or above the age of legal consent in the jurisdiction in which the study is taking place
* Infant must be healthy in the investigator's clinical judgment (and the parent(s)/guardian) on the basis of medical history, physical examination, vital signs and clinical laboratory tests performed at screening
* Infant has received all routine immunizations appropriate for his or her age at the time of enrollment as documented in the vaccination cards presented by the parent(s)/guardian. Participants are allowed to catch up on routine immunizations if needed (support for beneficial vaccines may be offered to participants)
* Extension Phase: Prior enrollment in the control arm of the main study and did not withdraw consent, and receipt of at least the first vaccination (Dose 1) in the main study

Exclusion Criteria

* Having received any candidate or other Ebola vaccine
* History of Ebola virus disease (EVD), or prior exposure to Ebola virus, including travel to an area with a current Ebola outbreak less than 1 month prior to screening
* Having received any experimental candidate Ad26- or modified vaccinia ankara (MVA)-based vaccine in the past
* Known allergy or history of anaphylaxis or other serious adverse reactions to vaccines or vaccine products (including any of the constituents of the study vaccines \[for example, polysorbate 80, ethylenediaminetetraacetic acid (EDTA) or L-histidine for Ad26.ZEBOV vaccine; tris (hydroxymethyl)-amino methane (THAM) for MVA-BN-Filo vaccine and Neisseria meningitidis polysaccharide or tetanus toxoid for MenACWY\]), including known allergy to chicken or egg proteins and aminoglycosides (gentamicin)
* Presence of acute illness (this does not include minor illnesses such as mild diarrhea or mild upper respiratory tract infection) or axillary temperature greater than or equal to (\>=) 37.5 degree celsius on Day 1. Participants with such symptoms will be excluded from enrollment at that time but may be rescheduled for enrollment at a later date
* Extension Phase: Having received any candidate or other Ebola vaccine

Minimum Eligible Age

4 Months

Maximum Eligible Age

11 Months

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes